GLIPIZIDE-GITS AND METFORMIN ALONE VS COMBINATION THERAPY IN NIDDM

具体目标 1.比较口服降糖药格列吡嗪控释片与 二甲双胍单药或联合用药对肝葡萄糖生成的影响 NIDDM患者。 2.比较Sustacal治疗的胰岛素分泌反应， 接受格列吡嗪-GITS或二甲双胍单药或联合给药的NIDDM。 这是一个假设，这一建议的组合，一个口头的 改善胰岛素分泌的降糖药（格列吡嗪）， 在以下治疗方案中改善胰岛素作用（Metabolic）： 与任一药物相比，NIDDM患者将提供更好的耐受性 通过对胰岛素分泌和作用的协同作用单独给药。

SPECIFIC AIMS 1. To compare the effect of oral hypoglycemic agents Glipizide-GITS and Metformin alone or in combination on hepatic glucose production in patients with NIDDM. 2. To compare insulin secretory responses to Sustacal in patients with NIDDM receiving Glipizide-GITS or Metformin alone or in combination. It is the hypothesis of this proposal that the combination of an oral hypoglycemic agent that improves insulin secretion (Glipizide) with one that improves insulin action (Metformin) in the treatment regiment of NIDDM patients will provide improved glycemia compared to either agent alone through a synergistic effect on insulin secretion and action.